TuHURA Biosciences Return on Equity (ROE) Growth & History (HURA)
TuHURA Biosciences's return on equity was −169.18% for fiscal 2025.
View full TuHURA Biosciences company overviewTuHURA Biosciences annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −169.18% | +398.78 pp |
| 2024 · Dec 31 | 2024-12-31 | −567.96% | — |
| 2023 · Jun 30 | 2023-06-30 | −224.77% | −22.22 pp |
| 2022 | 2022-12-31 | −77.74% | — |
| 2022 | 2022-06-30 | −202.55% | +503.80 pp |
| 2021 | 2021-06-30 | −706.34% | +111.76 pp |
| 2020 | 2020-06-30 | −818.11% | −600.68 pp |
| 2019 | 2019-06-30 | −217.42% | −402.85 pp |
| 2018 | 2018-06-30 | 185.43% | +44.10 pp |
| 2017 | 2017-06-30 | 141.32% | −297.83 pp |
| 2016 | 2016-06-30 | 439.15% | — |
| 2011 · Dec 31 | 2011-12-31 | −40,296.58% | — |
TuHURA Biosciences quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −44.25% | +20.75 pp |
| Q1 2026 | 2026-03-31 | −34.16% | +20.35 pp |
| Q4 2025 | 2025-12-31 | −35.86% | +65.53 pp |
| Q3 2025 | 2025-09-30 | −39.21% | — |
| Q2 2025 | 2025-06-30 | −65.00% | — |
| Q1 2025 · Mar 31 | 2025-03-31 | −54.51% | — |
| Q4 2024 | 2024-12-31 | −101.39% | — |
| Q4 2023 | 2023-06-30 | −147.66% | −96.24 pp |
| Q3 2023 | 2023-03-31 | −62.87% | −17.26 pp |
| Q2 2023 | 2022-12-31 | −42.60% | −7.17 pp |
| Q1 2023 | 2022-09-30 | −42.93% | −2.81 pp |
| Q4 2022 | 2022-06-30 | −51.42% | −0.99 pp |
| Q3 2022 | 2022-03-31 | −45.61% | −6.23 pp |
| Q2 2022 | 2021-12-31 | −35.43% | −7.04 pp |
| Q1 2022 | 2021-09-30 | −40.12% | +147.40 pp |
| Q4 2021 | 2021-06-30 | −50.43% | +141.49 pp |
| Q3 2021 | 2021-03-31 | −39.37% | +3.16 pp |
| Q2 2021 | 2020-12-31 | −28.39% | −0.56 pp |
| Q1 2021 | 2020-09-30 | −187.52% | −151.80 pp |
| Q4 2020 | 2020-06-30 | −191.92% | −31.86 pp |
| Q3 2020 | 2020-03-31 | −42.53% | +40.08 pp |
| Q2 2020 | 2019-12-31 | −27.83% | +28.38 pp |
| Q1 2020 | 2019-09-30 | −35.72% | +8.03 pp |
| Q4 2019 | 2019-06-30 | −160.06% | −463.99 pp |
| Q3 2019 | 2019-03-31 | −82.61% | −49.36 pp |
| Q2 2019 | 2018-12-31 | −56.20% | −28.59 pp |
| Q1 2019 | 2018-09-30 | −43.75% | −16.40 pp |
| Q4 2018 | 2018-06-30 | 303.92% | −43.45 pp |
| Q3 2018 | 2018-03-31 | −33.25% | +61.78 pp |
| Q2 2018 | 2017-12-31 | −27.61% | +11.99 pp |
| Q1 2018 | 2017-09-30 | −27.35% | +24.51 pp |
| Q4 2017 | 2017-06-30 | 347.37% | −337.01 pp |
| Q3 2017 | 2017-03-31 | −95.03% | — |
| Q2 2017 | 2016-12-31 | −39.60% | — |
| Q1 2017 | 2016-09-30 | −51.86% | — |
| Q4 2016 | 2016-06-30 | 684.38% | +2023.84 pp |
| Q4 2015 | 2015-06-30 | −1,339.46% | — |
| Q3 2015 | 2015-03-31 | 26.49% | — |
| Q2 2015 | 2014-12-31 | −47.53% | — |
| Q4 2011 · Dec 31 | 2011-12-31 | −791.59% | — |
| Q1 2012 · Sep 30 | 2011-09-30 | −44.01% | — |
TuHURA Biosciences return on equity trends
Between the periods ended 2011-12-31 and 2025-12-31, TuHURA Biosciences's return on equity increased from −40,296.58% to −169.18%, a change of +40127.40 percentage points. The latest reported quarter, Q2 2026, shows −44.25%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TuHURA Biosciences source filings ↗